The anti-calcitonin gene-related peptide monoclonal antibody fremanezumab has been shown to reduce migraines compared to placebo, however experts say data is still needed on the long-term safety of the drug class. The phase III randomised trial involved 875 adults with episodic migraine, in whom multiple medication classes had not previously failed. From baseline to 12 weeks, mean ...
mAb effective in migraine but safety questions remain
By Nicola Garrett
25 May 2018